Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 25, 2026International Archives of Allergy and Immunology

CD300a as a Potential Immune Checkpoint in Breast Cancer: Insights from in vivo and in vitro Models.

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMicha Ben-ZimraSNShiran NiazovFAFidan Rahimli Alekberli

Discussion

Loading...

Member takes

Overview

In vivo and in vitro models explore CD300a's role in suppressing anti-tumor immunity in breast cancer.

Key Points

  • This research aims to investigate the role of CD300a in regulating anti-tumor immunity in breast cancer models.
  • Induced 4T1 breast cancer model in wild-type (WT) and CD300a-knockout (KO) mice.
  • Evaluated tumor-associated mast cells activation using toluidine blue staining.
  • Co-cultured 4T1 cells with WT or CD300a-KO bone marrow-derived mast cells (BMMCs) and assessed cell viability with trypan blue.
  • Co-cultured human MDA-231 cells with cord blood-derived mast cells and added soluble CD300a-Fc.
  • Performed FACS analysis for MDA-231 cell viability and western blot for CD300a signal transduction in CBMCs.
  • CD300a-KO mice exhibited smaller 4T1 tumors with more activated mast cells compared to WT mice.
  • Co-culture with CD300a-KO BMMCs further reduced 4T1 cell growth compared to WT BMMCs.
  • MDA-231 cell growth decreased when co-cultured with CBMCs treated with CD300a-Fc, indicating interference with pro-tumorigenic interactions.
  • Activation of the CD300a signal transduction pathway in CBMCs co-cultured with MDA-231 cells was inhibited by CD300a-Fc treatment.

Cite This Study

Ben-Zimra et al. (2026) studied this question.

synapsesocial.com/papers/69c37acab34aaaeb1a67cafehttps://doi.org/10.1159/000551604
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The inhibitory receptor CD300a functions as an immune checkpoint in a mouse model of breast cancer2024
  2. 2Targeting CD300ld to normalize the tumor microenvironment: an emerging insight in cancer immunotherapy2024 · 3 citations
  3. 3Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies2024 · 4 citations
  4. 4CD300e as a Driver of Immunosuppressive Tumor Microenvironment in Colorectal Cancer2024
  5. 5CD300e is a driver of the immunosuppressive tumor microenvironment and colorectal cancer progression via macrophage reprogramming2025 · 2 citations